LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system

LivaNova PLC

2026-Q1 EPS reported $0.40 revenue$362,258,000

Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.
Raised FY2026 constant-currency revenue growth guidance to 7.0%-8.0% (up 100bps); adjusted EPS guidance raised to $4.20-$4.30.
Received FDA PMA for aura6000 HGNS system for moderate-to-severe OSA; no CCC contraindication or pre-implant DISE required.
Published 12-month OSPREY trial results in Annals of Internal Medicine; demonstrated clinically significant responses.
Q1 adjusted free cash flow $3.8M; maintained FY2026 adjusted FCF guidance $160M-$180M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LivaNova PLC reported the quarter ended March 31, 2026 results: revenue $362.3 million, EPS $0.40. Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $362.3 million
EPS: $0.40
Guidance: raised
Result: reported results

Exact text from the filing

First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period • First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98

View on SEC.gov

Browse all earnings releases →

LivaNova PLC filing history →

Source: SEC EDGAR

accession 0001639691-26-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.